Ariad Patent Claims In Suit V. Eli Lilly Invalid: Court

Law360, New York (April 9, 2009, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has handed a win to drugmaker Eli Lilly & Co. in a long-running patent battle launched by Ariad Pharmaceuticals Inc. over the drugs Evista and Xigris, finding four claims of Ariad's patent invalid.

In a decision issued April 3, the Federal Circuit tossed the patent claims asserted against Lilly related to Evista, an osteoporosis treatment, and Xigris, a treatment for severe sepsis, ruling that those four claims of the Ariad patent were invalid because the written descriptions...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.